BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/19/2015 5:28:00 PM | Browse: 1446 | Download: 1809
 |
Received |
|
2014-10-29 08:44 |
|
Peer-Review Started |
|
2014-11-01 11:42 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-12-16 13:16 |
|
Revised |
|
2014-12-27 22:33 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2015-01-21 20:58 |
|
Second Decision by Editor-in-Chief |
|
2015-01-23 18:15 |
|
Final Decision by Editorial Office Director |
|
2015-02-02 20:16 |
|
Articles in Press |
|
2015-02-02 20:16 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-04-28 14:13 |
|
Publish the Manuscript Online |
|
2015-05-19 17:28 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Stefano Colagrande, Francesco Regini, Gian Giacomo Taliani, Cosimo Nardi and Andrea Lorenzo Inghilesi |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Protocollo TESORM by Regione Toscana |
|
| Università degli Studi di Firenze |
|
| Bayer Health Care s.p.a |
|
|
| Corresponding Author |
Stefano Colagrande, MD, Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, Università degli Studi di Firenze-Azienda Ospedaliero-Universitaria Careggi, Radiodiagnostica 2, Largo Brambilla 3, 50134 Florence,
Italy. stefano.colagrande@unifi.it
|
| Key Words |
Modified Response Evaluation Criteria in Solid Tumors; Diffusion weighted imaging; Barcelona clinic liver cancer; Advanced hepatocellular carcinoma; Sorafenib; Advanced hepatocellular carcinoma second line therapies; Perfusion weighted imaging; Response evaluation; Hepatocellular carcinoma follow-up; Response Evaluation Criteria in Solid Tumors |
| Core Tip |
Advanced stage hepatocellular carcinoma comprehends a wide range of patients with different general conditions. The main therapeutic option is represented by sorafenib. Although the treatment has shown a significant increase in mean overall survival, only a part of patients actually shows benefits. Differentiating responder from non-responder patients is a pivotal challenge for the future. In particular, finding parameters quantitatively describing perfusion grade, and then able to predict the sensitivity of the lesions to anti-angiogenic agents could help stratifying patients in terms of responsiveness before the beginning of the therapy itself. This would bring a great help in management of these patients.
|
| Publish Date |
2015-05-19 17:28 |
| Citation |
Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 |
| URL |
http://www.wjgnet.com/1948-5182/full/v7/i8/1041.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v7.i8.1041 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
